В-КЛІТИННІ НОВОУТВОРЕННЯ ЛІМФОЇДНОЇ ТКАНИНИ У П’ЯТОМУ ПЕРЕГЛЯДІ КЛАСИФІКАЦІЇ ВООЗ ГЕМАТОЛІМФОЇДНИХ ПУХЛИН (2022 р.) 2. Пухлини зі зрілих В-клітин, плазмоклітинні пухлини та парапротеінемії
DOI:
https://doi.org/10.15407/oncology.2023.03.159Ключові слова:
Всесвітня організація охорони здоров’я, діагностика, класифікація, лімфоїдні пухлиниАнотація
Нове й більш глибоке розуміння патогенезу новоутворень лімфоїдної та кровотворної тканин вимагає постійного перегляду їх класифікації. У 2022 р. фахівцями ВООЗ було підготовлене чергове 5-е видання такої класифікації. У попередньому повідомленні (Онкологія 2023; 25 (2): 89–103) були обговорені ключові етапи створення сучасної класифікації ВООЗ новоутворень лімфоїдної та кровотворної тканин, основні принципи побудови переглянутої (2022 р.) класифікації гематолімфоїдних пухлин, а також детально розглянуто розділи “пухлиноподібні ураження з переважанням B-клітин” та “пухлини з В-клітин-попередників”.
Метою даного повідомлення є перелік та пояснення основних змін у 5-й редакції класифікації ВООЗ гематолімфоїдних пухлин, які стосуються пухлин зі зрілих В-клітин, плазмоклітинних пухлин та парапротеїнемій. Головну увагу зосереджено на практичних аспектах використання нової класифікації ВООЗ для верифікації злоякісних лімфоїдних новоутворень В-клітинного походження з урахуванням визначальних молекулярно-біологічних ознак окремих нозологічних форм та їх підтипів. Внесені до класифікації зміни є ключем для вибору стратегії терапії онкогематологічних хворих та покращення результатів їх лікування.
Посилання
Philchenkov AA, Zavelevich MP, Abramenko IV. B-cell lymphoid neoplasms in the 5th edition of the WHO Classification of Hematolymphoid Tumors (2022). 1. General principles of classification. Precursor B-cell neoplasms. Oncology (Kyiv) 2023; 25 (2): 89–103. doi: https://doi.org/10.15407/oncology.2023.02.089 (in Ukrainian).
Campo E, Jaffe ES, Cook JR, et al. The International Consensus Classification of Mature Lymphoid Neoplasms: A report from the Clinical Advisory Committee. Blood 2022; 140 (11): 1229–53. doi: https://doi.org/10.1182/blood.2022015851.
Arber DA, Orazi A, Hasserjian RP, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: Integrating morphologic, clinical, and genomic data. Blood 2022; 140 (11): 1200–28. doi: https://doi.org/10.1182/blood.2022015850.
Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: Lymphoid neoplasms. Leukemia. 2022; 36 (7): 1720–48. doi: https://doi.org/10.1038/s41375-022-01620-2.
Heraud I, Mauduit C, Golfier C, et al. Monoclonal B-cell lymphocytosis with a non-CLL immunophenotype — Review of 34 cases. Ann Biol Clin (Paris) 2023; 81 (2): 162–7. doi: https://doi.org/10.1684/abc.2023.1803.
Sander B, Campo E, Hsi ED. Chronic lymphocytic leukaemia/ small lymphocytic lymphoma and mantle cell lymphoma: From early lesions to transformation. Virchows Arch 2023; 482 (1): 131–45. doi: https://doi.org/10.1007/s00428-022-03460-y.
Strati P, Shanafelt TD. Monoclonal B-cell lymphocytosis and early-stage chronic lymphocytic leukemia: Diagnosis, natural history, and risk stratification. Blood 2015; 126 (4): 454–62. doi: https://doi.org/10.1182/blood-2015-02-585059.
Parikh SA, Achenbach SJ, Rabe KG, et al. The risk of coronavirus disease 2019 (COVID-19) among individuals with monoclonal B cell lymphocytosis. Blood Cancer J 2022; 12 (11): 159. doi: https://doi.org/10.1038/s41408-022-00754-x.
Philchenkov AA, Zavelevich MP, Abramenko IV, et al. Current state of laboratory diagnosis of mature B-cell lymphoid neoplasms in Ukraine. Oncology (Kyiv) 2022; 24 (3): 184–96. doi: https://doi.org/10.32471/oncology.2663-7928.t-24-3-2022-g.10753 (in Ukrainian).
Tiacci E, Trifonov V, Schiavoni G, et al. BRAF mutations in hairy-cell leukemia. N Engl J Med 2011; 364 (24): 2305–15. doi: https://doi.org/10.1056/nejmoa1014209.
Maitre E, Paillassa J, Troussard X. Novel targeted treatments in hairy cell leukemia and other hairy cell-like disorders. Front Oncol 2022; 12: 1068981. doi: https://doi.org/10.3389/fonc.2022.1068981.
Martinez D, Navarro A, Martinez-Trillos A, et al. NOTCH1, TP53, and MAP2K1 mutations in splenic diffuse red pulp small B-cell lymphoma are associated with progressive disease. Am J Surg Pathol 2016; 40 (2): 192–201. doi: https://doi.org/10.1097/PAS.0000000000000523.
Yilmaz E, Chhina A, Nava VE, et al. A review on splenic diffuse red pulp small B-cell lymphoma. Curr Oncol 2021; 28 (6): 5148–54. doi: https://doi.org/10.3390/curroncol2806043.
Laurent C, Cook JR, Yoshino T, et al. Follicular lymphoma and marginal zone lymphoma: How many diseases? Virchows Arch 2023; 482 (1): 149–62. doi: https://doi.org/10.1007/s00428-022-03432-2.
Polonis K, Schultz MJ, Olteanu H, et al. Detection of cryptic CCND1 rearrangements in mantle cell lymphoma by next generation sequencing. Ann Diagn Pathol 2020; 46: 151533. doi: https://doi.org/10.1016/j.anndiagpath.2020.151533.
Soliman DS, Ibrahim F, Fernyhough LJ, et al. Concurrent presentation of hairy cell leukemia and mantle cell lymphoma (leukemic non-nodal variant): An extremely rare composite lymphoma. J Hematol 2022; 11 (1): 21–8. doi: https://doi.org/10.14740/jh942.
Nadeu F, Martin-Garcia D, Clot G, et al. Genomic and epigenomic insights into the origin, pathogenesis, and clinical behavior of mantle cell lymphoma subtypes. Blood 2020; 136 (12): 1419–32. doi: https://doi.org/10.1182/blood.202000528.
Kurz KS, Kalmbach S, Ott M, et al. Follicular lymphoma in the 5th Edition of the WHO-Classification of Haematolymphoid Neoplasms — Updated classification and new biological data. Cancers (Basel) 2023; 15 (3): 785. doi: https://doi.org/10.3390/cancers15030785.
Xian RR, Xie Y, Haley LM, et al. CREBBP and STAT6 comutation and 16p13 and 1p36 loss define the t(14;18)-negative diffuse variant of follicular lymphoma. Blood Cancer J 2020; 10 (6): 69. doi: https://doi.org/10.1038/s41408-020-0335-0.
Reddy A, Zhang J, Davis NS, et al. Genetic and functional drivers of diffuse large B cell lymphoma. Cell 2017; 171 (2): 481–94. doi: https://doi.org/10.1016/j.cell.2017.09.027.
Collinge B, Ben-Neriah S, Chong L, et al. The impact of MYC and BCL2 structural variants in tumors of DLBCL morphology and mechanisms of false-negative MYC IHC. Blood 2021; 137 (16): 2196–208. doi: https://doi.org/10.1182/blood.2020007193.
Wang H, Zhang Q, Liu Q, et al. Fluid overload-associated large B-cell lymphoma with primary biliary cirrhosis: A case report. Front Oncol 2023; 13: 1145540. doi: https://doi.org/10.3389/fonc.2023.1145540.
Leoncini L. Epstein-Barr virus positivity as a defining pathogenetic feature of Burkitt lymphoma subtypes. Br J Haematol 2022; 196 (3): 468–70. doi: https://doi.org/10.1111/bjh.17922.
Cesarman E, Chadburn A, Rubinstein PG. KSHV/HHV8-mediated hematologic diseases. Blood 2022; 139 (7): 1013–25. doi: https://doi.org/10.1182/blood.2020005470.
Chang KL, Arber DA, Weiss LM. Lymph nodes. In: Modern Surgical Pathology, 2nd Edition, Vol 2. Weidner N, Cote RJ, Suster S, Weiss LM (eds). London: Elsevier Health Sciences, 2009: 1431–511.
Louissaint A., Ferry J., Soupir C, et al. Infectious mononucleosis mimicking lymphoma: Distinguishing morphological and immunophenotypic features. Mod Pathol 2012; 25 (8): 1149–59. doi: https://doi.org/10.1038/modpathol.2012.70.
Nakanishi R, Ishida M, Hodohara K, et al. Occurrence of Epstein–Barr virus-associated plasmacytic lymphoproliferative disorder after antithymocyte globulin therapy for aplastic anemia: A case report with review of the literature. Int J Clin Exp Pathol 2014; 7 (4): 1748–54. PMID: 24817974.
Natkunam Y, Gratzinger D, Chadburn A, et al. Immunodeficiency- associated lymphoproliferative disorders: Time for reappraisal? Blood 2018; 132 (18): 1871–8. doi: https://doi.org/10.1182/blood-2018-04-842559.
Dojcinov SD, Venkataraman G, Raffeld M, et al. EBV positive mucocutaneous ulcer — A study of 26 cases associated with various sources of immunosuppression. Am J Surg Pathol 2010; 34 (3): 405–17. doi: https://doi.org/10.1097/PAS.0b013e3181cf8622.
Roberts TK, Chen X, Liao JJ. Diagnostic and therapeutic challenges of EBV-positive mucocutaneous ulcer: A case report and systematic review of the literature. Exp Hematol Oncol 2016; 5: 13. doi: https://doi.org/10.1186/s40164-016-0042-5.
Berhan A, Bayleyegn B, Getaneh Z. HIV/AIDS associated lymphoma: Review. Blood Lymphat Cancer 2022; 12: 31–45. doi: https://doi.org/10.2147/BLCTT.S361320.
Abbas F, El Kossi M, Shaheen IS, et al. Post-transplantation lymphoproliferative disorders: Current concepts and future therapeutic approaches. World J Transplant 2020; 10 (2): 29–46. doi: https://doi.org/10.5500/wjt.v10.i2.29.
Mancuso S, Carlisi M, Santoro M, et al. Immunosenescence and lymphomagenesis. Immun Ageing 2018; 15: 22. doi: https://doi.org/10.1186/s12979-018-0130-y.
Shapiro RS. Malignancies in the setting of primary immunodeficiency: Implications for hematologists/oncologists. Am J Hematol 2011; 86 (1): 48–55. doi: https://doi.org/10.1002/ajh.21903.
Herber M, Mertz P, Dieudonné Y, et al. Primary immunodeficiencies and lymphoma: A systematic review of literature. Leuk Lymphoma 2020; 61 (2): 274–84. doi: https://doi.org/10.1080/10428194.2019.1672056.
Gluzman DF, Zavelevich MP, Philchenkov AA, et al. Longterm exposure to low doses of ionizing radiation and COVID-19 pandemic: Oncohematological aspects. Exp Oncol 2021; 43 (2): 189–92. doi: https://doi.org/10.32471/exp-oncology.2312-8852.vol-43-no-2.16434.
Gluzman DF, Zavelevich MP, Philchenkov AA, et al. Immunodeficiency- associated lymphoproliferative disorders and lymphoid neoplasms in post-COVID-19 pandemic era. Exp Oncol 2021; 43 (1): 87–91. doi: https://doi.org/10.32471/exponcology.2312-8852.vol-43-no-1.15795.
Kaseb H, Babiker HM. Hodgkin Lymphoma. [Updated 2023 Jun 26]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023. PMID: 29763144. Available from: https://www.ncbi.nlm.nih.gov/books/NBK499969.
Grewal RK, Chetty M, Abayomi EA, et al. Use of flow cytometry in the phenotypic diagnosis of Hodgkin’s lymphoma. Cytometry B Clin Cytom 2019; 96 (2): 116–27. doi: https://doi.org/10.1002/cyto.b.21724.
Rets AV, Gottesman SR. Nodular lymphocyte predominant Hodgkin lymphoma versus T-cell/histiocyte-rich large Bcell lymphoma: A diagnostic challenge. Case Rep Pathol 2014; 2014: 956217. doi: https://doi.org/10.1155/2014/956217.
Fan Z, Natkunam Y, Bair E, et al. Characterization of variant patterns of nodular lymphocyte predominant Hodgkin lymphoma with immunohistologic and clinical correlation. Am J Surg Pathol 2003; 27 (10): 1346–56. doi: https://doi.org/10.1097/00000478-200310000-00007.
Eichenauer DA, Engert A. Nodular lymphocyte-predominant Hodgkin lymphoma: A unique disease deserving unique management. Hematology Am Soc Hematol Educ Program 2017; 2017 (1): 324–8. doi: https://doi.org/10.1182/asheducation-2017.1.324.
Berentsen S, Barcellini W. Autoimmune hemolytic anemias. N Engl J Med 2021; 385 (15): 1407–19. doi: https://doi.org/10.1056/NEJMra2033982.
Khwaja J, D’Sa S, Minnema MC, et al. IgM monoclonal gammopathies of clinical significance: Diagnosis and management. Haematologica 2022; 107 (9): 2037–50. doi: https://doi.org/10.3324/haematol.2022.280953.
Rajkumar SV, Kyle RA, Therneau TM, et al. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood 2005; 106 (3): 812–7. doi: https://doi.org/10.1182/blood-2005-03-1038.
Leung N, Bridoux F, Batuman V, et al. The evaluation of monoclonal gammopathy of renal significance: A consensus report of the International Kidney and Monoclonal Gammopathy Research Group. Nat Rev Nephrol 2019; 15 (1): 45–59. doi: https://doi.org/10.1038/s41581-018-0077-4.
Leung N, Bridoux F, Nasr SH. Monoclonal gammopathy of renal significance. N Engl J Med 2021; 384 (20): 1931–41. doi: https://doi.org/10.1056/NEJMra1810907.
Kumar SK, Gertz MA, Dispenzieri A. Validation of Mayo Clinic Staging System for light chain amyloidosis with highsensitivity troponin. J Clin Oncol 2019; 37 (2): 171–3. doi: https://doi.org/10.1200/JCO.18.01398.
Gertz MA. Immunoglobulin light chain amyloidosis: 2020 update on diagnosis, prognosis, and treatment. Am J Hematol 2020; 95 (7): 848–60. doi: https://doi.org/10.1002/ajh.25819.
Joly F, Cohen C, Javaugue V, et al. Randall-type monoclonal immunoglobulin deposition disease: Novel insights from a nationwide cohort study. Blood 2019; 133 (6): 576–87. doi: https://doi.org/10.1182/blood-2018-09-872028.
Rambaud JC, Bognel C, Prost A, et al. Clinico-pathological study of a patient with “Mediterranean” type of abdominal lymphoma and a new type of IgA abnormality (“alpha chain disease”). Digestion 1968; 1 (6): 321–36. doi: https://doi.org/10.1159/000196874.
Ria R, Dammacco F, Vacca A. Heavy-chain diseases and myeloma-associated Fanconi syndrome: An update. Mediterr J Hematol Infect Dis 2018; 10 (1): e2018011. doi: https://doi.org/10.4084/MJHID.2018.011.
Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol 2005; 23 (15): 3412–20. doi: https://doi.org/10.1200/JCO.2005.04.242.
Palumbo A, Avet-Loiseau H, Oliva S, et al. Revised International Staging System for multiple myeloma: A report from International Myeloma Working Group. J Clin Oncol 2015; 33 (26): 2863–9. doi: https://doi.org/10.1200/JCO.2015.61.2267.
Flores-Montero J, de Tute R, Paiva B, et al. Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma. Cytometry B Clin Cytom 2016; 90 (1): 61–72. doi: https://doi.org/10.1002/cyto.b.21265.
Rajkumar SV, Kumar S, Lonial S, et al. Smoldering multiple myeloma current treatment algorithms. Blood Cancer J 2022; 12 (9): 129. doi: https://doi.org/10.1038/s41408-022-00719-0.
Caers J, Paiva B, Zamagni E, et al. Diagnosis, treatment, and response assessment in solitary plasmacytoma: Updated recommendations from a European Expert Panel. J Hematol Oncol 2018; 11 (1): 10. doi: https://doi.org/10.1186/s13045-017-0549-1.
Bardwick PA, Zvaifler NJ, Gill GN, et al. Plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes: the POEMS syndrome. Report on two cases and a review of the literature. Medicine (Baltimore) 1980; 59 (4): 311–22. doi: https://doi.org/10.1097/00005792-198007000-00006.
Dispenzieri A. POEMS syndrome: 2014 update on diagnosis, risk-stratification, and management. Am J Hematol 2014; 89 (2): 214–23. doi: https://doi.org/10.1002/ajh.23644.
Sykes DB, Schroyens W, O’Connell C. The TEMPI syndrome — a novel multisystem disease. N Engl J Med 2011; 365 (5): 475–7. doi: https://doi.org/10.1056/NEJMc1106670.
Xu J, Liu W, Fan F, et al. TEMPI syndrome: Update on clinical features, management, and pathogenesis. Front Endocrinol (Lausanne) 2022; 13: 886961. doi: https://doi.org/10.3389/fendo.2022.886961.
Lenormand C, Marzolf G, Lipsker D. AESOP syndrome: A potential life-saving and early clue to the diagnosis of POEMS syndrome. Clin Dermatol 2021; 39 (2): 215–9. doi: https://doi.org/10.1016/j.clindermatol.2020.10.002.
